Comparative Pharmacology
Head-to-head clinical analysis: BETAPAR versus CORTRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPAR versus CORTRIL.
BETAPAR vs CORTRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist that stimulates adenylyl cyclase, increasing cAMP levels, leading to bronchodilation.
Cortril (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators and suppression of immune response.
Initial: 25 mg orally twice daily; may increase gradually to 100 mg twice daily based on tolerance and response.
Hydrocortisone (Cortril) for adrenal insufficiency: 20-30 mg orally daily divided into two or three doses. For acute conditions, IV or IM hydrocortisone sodium succinate 100 mg every 8 hours.
None Documented
None Documented
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 10-20 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 1.5–2.5 hours. Clinically, the biologic half-life (duration of ACTH suppression) is longer (8–12 hours).
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; the remainder undergoes hepatic metabolism.
Renal (95% as free cortisol and metabolites, primarily tetrahydrocortisol and glucuronide conjugates). Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Corticosteroid
Corticosteroid